Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment

Current Psychiatry Reviews

Volumn 12, Issue 3, 2016, Pages 278-290

  Nelson, James C ^a   Zhang, Peter ^b   Skuban, Aleksandar ^b   Hobart, Mary ^b   Weiss, Catherine ^b   Weiller, Emmanuelle ^c   Thase, Michael E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjunctive therapy; Antipsychotics; Brexpiprazole; Clinical trials; Major depressive disorder; Safety

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BREXPIPRAZOLE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN; SERTRALINE; VENLAFAXINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AKATHISIA; ANXIETY DISORDER; APPETITE DISORDER; ASSESSMENT OF HUMANS; BARNES AKATHISIA SCALE; COLUMBIA SUICIDE SEVERITY RATING SCALE; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DYSKINESIA; DYSTONIA; FATIGUE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MASSACHUSETTS GENERAL HOSPITAL ANTIDEPRESSANT TREATMENT RESPONSE QUESTIONNAIRE; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SIMPSON ANGUS SCALE; SOMNOLENCE; SUICIDE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 85006952481     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/1573400512666160816095900     Document Type: Review

References (36)

1. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013; 43: 471-81.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.
3. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry 2008; 9: 102-14.
4. Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71: 43-64.
5. Philip NS, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 2010; 11: 709-22.
6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17.
7. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-91.
8. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122: 39-48.
9. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72: 1063-71.
10. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013; 27: 879-911.
11. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589-604.
12. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6: 2091-101.
13. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 605-14.
14. Laoutidis ZG, Luckhaus C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2014; 17: 823-32.
15. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol 2015; 25: 505-11.
16. Thase ME, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study. Neuropsychopharmacology 2011; 36: S302-S4.
17. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76: 1232-40.
18. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224-31.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IVTR) 2000.
20. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther 2010; 16: 322-5.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
24. Guy W (1976). ECDEU assessment manual for psychopharmacology (revised). Hamilton anxiety scale. M. Hamilton, US Department of Health, Education, and Welfare publication (ADM) 76-338, Rockville, MD: National Institute of Mental Health: 193-8.
25. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266-77.
26. Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom 2001; 70: 221-5.
27. Nelson JC. Adjunctive Ziprasidone in Major Depression and the Current Status of Adjunctive Atypical Antipsychotics. Am J Psychiatry 2015; 172: 1176-8.
28. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382: 951-62.
29. Balt SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther 2011; 90: 179-83.
30. Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011; 7: 303-12.
31. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170-6.
32. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 (Suppl 9): 16-20.
33. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23: 477-92.
34. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-6.
35. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-26.
36. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27-35.